上市公司独立董事候选人声明与承诺 声明人 童作军 作为派斯双林生物制药股份有限公司 第 十 届董事会独立董事候选人,已充分了解并同意由提 名人 共青城胜帮英豪投资合伙企业(有限合伙)提名为派 斯双林生物制药股份有限公司(以下简称该公司)第 十 届 董事会独立董事候选人。现公开声明和保证,本人与该公 司之间不存在任何影响本人独立性的关系,且符合相关法 律、行政法规、部门规章、规范性文件和深圳证券交易所 业务规则对独立董事候选人任职资格及独立性的要求,具 体声明并承诺如下事项: 一、本人已经通过派斯双林生物制药股份有限公司第 九 届董事会提名委员会或者独立董事专门会议资格审查 ,提名人与本人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 圆 是 □ 否 如否,请详细说明: 二、本人不存在《中华人民共和国公司法》第一百四 十六条等规定不得担任公司董事的情形。 圆是 □ 否 如否,请详细说明: … 三、本人符合中国证监会《上市公司独立董事管理办 法》和深圳证券交易所业务规则规定的独立董事任职资格 和条件。 圆 是 ■ 否 如否,请详细说明: 四、本人符合该公司章程规定的独立董事任职条件。 圆 是 □ 否 如 ...

证券代码：000403 证券简称：派林生物 公告编号：2023-088 派斯双林生物制药股份有限公司 第九届监事会第二十二次会议（临时会议）决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第九届监事会第二十二 次会议（临时会议）于 2023 年 9 月 28 日以通讯方式召开，会议由公司监事会主席 周冠鑫先生召集并主持。会议应出席监事 5 人，实际出席监事 5 人，本次会议系临 时紧急会议，会议召集人和主持人周冠鑫先生对于要求召开临时紧急监事会作出说 明如下： 共青城胜帮英豪投资合伙企业（有限合伙）（以下简称"胜帮英豪"或"提议 人"）于 2023 年 9 月 16 日向公司董事会提交了《关于提请召开派斯双林生物制药 股份有限公司 2023 年第三次临时股东大会的函》，公司董事会在收到前述函件 10 日内并未作出反馈。 2023 年 9 月 27 日，公司监事会收到胜帮英豪提交的《关于提请召开派斯双林 生物制药股份有限公司 2023 年第三次临时股东大会的函》。根据《公司章程》 ...

登记号：MA1C6BEL323000016F2009 有效期：2023年9月20日至2025年9月20日 该单采血浆站经核准登记，准予执业。 证券代码：000403 证券简称：派林生物 公告编号：2023-087 派斯双林生物制药股份有限公司 关于庆安县派斯菲科单采血浆有限公司获得单采血浆许可证 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）全资子公司哈尔滨派斯 菲科生物制药有限公司下属庆安县派斯菲科单采血浆有限公司（以下简称"庆安浆 站"）收到黑龙江省卫生健康委员会签发的《单采血浆许可证》，现将主要信息公 告如下： 机构名称：庆安县派斯菲科单采血浆有限公司 地址：绥化市庆安县农商物流园道东 业务项目：采集健康人普通血浆和特免血浆 采浆区域（范围）：庆安县、绥棱县 二〇二三年九月二十一日 庆安浆站自本次取得《单采血浆许可证》之日起可正式采浆，庆安浆站实现采 浆有利于提升公司原料血浆供应能力，有利于提升公司经营业绩，对公司长期发展 具有积极作用。 特此公告。 派斯双林生物制药股份有限公司 董 事 会 ...

证券代码：000403 证券简称：派林生物 公告编号：2023-086 派斯双林生物制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第九届董事会第二十八次 会议（临时会议）于2023年9月13日以通讯方式召开，会议由公司董事长付绍兰女士 召集并主持。本次会议通知于2023年9月11日以通讯方式发出，会议应出席董事12人， 实际出席董事12人，会议程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事经过认真讨论，审议了以下议案： 1、《关于任命广东双林生物制药有限公司法定代表人的议案》 鉴于公司全资子公司广东双林生物制药有限公司（以下简称"广东双林"）执行 董事兼法定代表人袁华刚先生因个人原因，申请辞去广东双林执行董事兼法定代表 人职务，以及广东双林及其子公司所有其他职务，经审议同意任命广东双林总经理 闫晨先生兼任广东双林法定代表人。 表决结果：11 票同意、0 票反对、1 票弃权。本议案表决结果为通过。 第九届董事会第二十八次会议（临时会议）决 ...

证券代码：000403 证券简称：派林生物 公告编号：2023-085 派斯双林生物制药股份有限公司诉讼进展公告 近日，派斯双林生物制药股份有限公司（以下简称"公司"）收到广东省湛江 经济技术开发区人民法院《民事判决书》【（2022）粤0891民初4877号】，现将相 关情况公告如下： 一、诉讼事项的基本情况 根据公司与新疆德源生物工程有限公司（以下简称"新疆德源"）、吕献忠、 及新疆德源下属6家浆站于2021年11月18日签署的《战略合作协议之补充协议》的约 定，新疆德源将下属6家浆站80%的股权转让给公司子公司广东双林生物制药有限公 司（以下简称"广东双林"），具体内容详见公司于2021年11月18日发布的《关于 签订<战略合作协议之补充协议>的公告》（公告编号：2021-099） 2022年7月22日，新疆德源的股东之一浙江豪普森生物识别应用有限公司（以下 简称"浙江豪普森"）向法院起诉，要求广东双林将上述合作浆站的80%股权转回 给温宿县德源单采血浆公司名下。 二、判决结果 近日公司收到广东省湛江经济技术开发区人民法院《民事判决书》【（2022） 粤0891民初4877号】，湛江经济技术开发区人民法院 ...

证券代码：000403 证券简称：派林生物 公告编号：2023-084 派斯双林生物制药股份有限公司 关于公司第一大股东一致行动人沈和平先生增持公司股份计划 的公告 本次增持主体沈和平先生保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司""上市公司"）近日收到公司第 一大股东共青城胜帮英豪投资合伙企业（有限合伙）（以下简称"胜帮英豪"）的关 联方胜帮科技股份有限公司（以下简称"胜帮科技"）持股25.78%的股东兼董事沈和 平先生拟增持上市公司股票的《增持计划告知函》，基于对上市公司未来发展前景的 信心和对上市公司价值的高度认可，沈和平先生计划自上市公司公告披露之日起6个 月内（法律法规及深圳证券交易所业务规则等有关规定不允许增持的期间除外）以自 有资金或自筹资金通过深圳证券交易所交易系统增持公司股份，增持金额合计不低于 人民币1,000万元，不高于人民币2,000万元，本次增持计划价格不超过28元/股。现将 有关情况公告如下： 一、增持主体的基本情况 1、计划增持主体：沈和平先生 截至本函出具日，沈和平先生持有公司股份 0 股，占本公司 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥709,071,800.34, a decrease of 28.45% compared to ¥991,052,056.37 in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2023 was ¥143,137,171.51, down 35.23% from ¥221,005,894.53 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥104,222,388.72, a decline of 45.68% compared to ¥191,856,661.41 in the same period last year[12]. - The net cash flow from operating activities was ¥156,384,423.12, which is a decrease of 31.48% from ¥228,241,860.95 in the previous year[12]. - The basic earnings per share for the first half of 2023 was ¥0.1958, down 35.29% from ¥0.3026 in the same period last year[12]. - The diluted earnings per share for the first half of 2023 was ¥0.1958, a decrease of 35.25% compared to ¥0.3024 in the previous year[12]. - The weighted average return on equity was 2.07%, down 1.36% from 3.43% in the same period last year[12]. - The company reported a total non-recurring gains and losses amounting to CNY 38,914,782.79 for the reporting period[14]. - The company achieved operating revenue of CNY 709.07 million, a decrease of 28.45% year-on-year, primarily due to limited sales volume of products[31]. - The net profit attributable to shareholders was CNY 143.14 million, down 35.23% year-on-year, while the net profit excluding non-recurring gains and losses was CNY 104.22 million, a decline of 45.68%[31]. Market Overview - The blood products market in China is currently valued at over CNY 400 billion, with significant growth potential compared to mature markets in Europe and the US[16]. - The global blood products market is projected to exceed USD 47.7 billion by 2027, indicating a robust growth trajectory[16]. - The domestic market for immunoglobulin and coagulation factor products is expected to expand significantly due to increased clinical applications and broader insurance coverage[23]. - The average sales prices and per capita usage of blood products in developed countries are significantly higher than in China, suggesting room for growth as income levels rise[24]. - The blood products industry in China is characterized by long-term supply shortages, with strict regulations on imports and production[22]. - The blood products industry is experiencing increasing concentration, with the top five global companies holding over 80% market share, indicating a trend towards oligopoly[25]. - The Chinese blood products market is expected to exceed 100 billion yuan in capacity, driven by economic growth, aging population, and increased clinical demand[25]. Company Strategy and Operations - The company operates in a highly regulated industry with only 28 licensed blood product manufacturers in China, creating high entry barriers[19]. - The company anticipates that the number of newly approved plasma collection stations will increase, leading to a sustained rise in plasma collection volume in the future[22]. - The company is positioned to benefit from the tightening global supply of blood products, creating opportunities for domestic alternatives and exports[24]. - The company has established a strategic cooperation with Xinjiang Deyuan to supply no less than 180 tons of plasma annually, extending the cooperation period by one year[26]. - Following the acquisition of Paisfiko, the company now has a total of 11 product varieties, ranking among the top three in the domestic blood products industry[27]. - The company anticipates a plasma collection volume exceeding 1,000 tons in 2023, entering the first tier of blood products producers[27]. - The company’s product range includes 8 varieties of human blood albumin and immunoglobulins, addressing critical medical needs such as shock and immune deficiencies[28]. - The company’s strategic expansion includes both organic growth and mergers, enhancing its competitive position in the blood products market[26]. - The company is focused on developing new products and technologies to meet the increasing demand for blood products in China[25]. - The company’s strategic initiatives aim to leverage resources, technology, and scale advantages to further increase market share[25]. Financial Position and Assets - Total assets at the end of the reporting period were ¥8,087,290,606.54, an increase of 1.31% from ¥7,982,324,465.77 at the end of the previous year[12]. - The net assets attributable to shareholders at the end of the reporting period were ¥6,938,535,011.90, up 1.03% from ¥6,867,524,210.96 at the end of the previous year[12]. - Cash and cash equivalents decreased to ¥889,546,022.34, representing 11.00% of total assets, down from 12.54% at the end of the previous year[44]. - Accounts receivable decreased to ¥458,931,120.12, making up 5.67% of total assets, down from 10.47% year-over-year[44]. - Inventory increased to ¥891,048,288.09, accounting for 11.02% of total assets, up from 7.81% last year[44]. - The company has a total of ¥40,644.96 million in unutilized raised funds, including ¥38,120.85 million that remains unused[49]. - The company has established a special account for managing raised funds, ensuring compliance with regulations and protecting investor interests[48]. Environmental Compliance - The company is not listed as a key pollutant discharge unit by environmental protection authorities, ensuring compliance with environmental regulations[82]. - The company has not experienced any pollution incidents or disputes during the reporting period and has not faced administrative penalties for violating environmental laws[83]. - The company obtained a new pollutant discharge permit valid until September 5, 2027, demonstrating its commitment to environmental compliance[84]. - The company received environmental approval for the expansion project on May 18, 2023, from the Harbin New Area Management Committee[85]. - The company has a valid wastewater discharge permit until December 9, 2026, obtained on December 10, 2021[85]. - The company reported a total nitrogen concentration of 1.83 mg/L at the main discharge point, compliant with discharge standards[87]. - The biochemical oxygen demand (BOD) was recorded at 3.815 mg/L, adhering to the specified concentration limits[87]. - The chemical oxygen demand (COD) was measured at 20.745 mg/L, within the allowable limits[87]. - The company reported zero instances of exceeding pollution discharge standards across various pollutants[86][88]. - The company maintains a hydrogen sulfide concentration of 1.4 mg/Nm³, compliant with pharmaceutical industry air pollution standards[88]. Shareholder and Corporate Governance - The company emphasizes shareholder rights protection and maintains transparent communication with investors[102]. - The company will not distribute cash dividends or issue bonus shares for the half-year period[72]. - The participation rate in the 2023 first extraordinary general meeting was 54.43%[70]. - The company approved the 2020 stock option and restricted stock incentive plan, granting 1.815 million stock options and 1.815 million restricted shares to 41 incentive recipients on May 19, 2020[74]. - The company has not experienced significant changes in project feasibility[51]. - The company has not sold any significant assets during the reporting period[62]. - The company reported no significant litigation or arbitration matters during the reporting period[108]. - There were no major related party transactions or significant contracts during the reporting period[109][111]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to recover from the revenue decline experienced in the first half of 2023[143]. - The overall financial health of the company is under scrutiny, with management likely to implement new strategies to address the losses and improve profitability moving forward[156].

Financial Performance - The company's operating revenue for 2022 was ¥2,405,188,425.37, an increase of 21.98% compared to ¥1,971,734,315.85 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥587,131,491.86, representing a growth of 50.14% from ¥391,063,978.44 in 2021[12]. - The net cash flow from operating activities reached ¥524,218,863.43, up 28.42% from ¥408,218,063.31 in the previous year[12]. - The basic earnings per share for 2022 was ¥0.8035, a 44.96% increase from ¥0.5543 in 2021[12]. - The total assets at the end of 2022 amounted to ¥7,982,324,465.77, reflecting a 12.62% increase from ¥7,087,797,976.53 at the end of 2021[12]. - The company reported a weighted average return on equity of 8.90% for 2022, compared to 7.03% in 2021[12]. - In 2022, the company achieved a revenue of CNY 2,405.19 million, representing a year-on-year growth of 21.98%[32]. - The net profit attributable to shareholders reached CNY 587.13 million, with a significant increase of 50.14% year-on-year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 517.57 million, showing a remarkable growth of 99.39%[32]. - Domestic market sales revenue was CNY 2,292.12 million, reflecting a year-on-year increase of 17.31%[32]. - Overseas sales revenue surged to CNY 113.06 million, marking an impressive growth of 534.38% year-on-year[32]. Market and Industry Insights - The blood products market is projected to exceed $47.7 billion globally by 2027, indicating significant growth potential for the company[18]. - The Chinese blood products market is currently valued at over ¥400 billion, with substantial growth opportunities compared to mature markets in Europe and the US[18]. - The company plans to leverage the tightening international supply of blood products to enhance domestic production and export opportunities[18]. - The blood products industry in China has a high entry barrier, with only 28 qualified production enterprises as of now[20]. - The market for blood products in China is expected to grow significantly, with potential market capacity surpassing 100 billion yuan in the future[26]. - The blood products market in China is characterized by long-term supply shortages, with strict regulations on plasma collection and imports[23]. - The industry is witnessing increasing concentration, with major players capturing over 80% of the market share globally[26]. Strategic Initiatives and Partnerships - The company plans to expand its market presence and enhance its product offerings through new technology development and strategic partnerships[3]. - The company has established a strategic cooperation agreement with Xinjiang Deyuan to supply no less than 180 tons of plasma annually for five years[27]. - The strategic partnership with Xinjiang Deyuan has strengthened plasma collection capabilities and improved supply stability[32]. - The company plans to expand its product offerings and enhance brand effects through multi-brand operations and resource integration[36]. - The company is actively pursuing overseas market registration and export opportunities in Southeast Asia, South America, and the Middle East[32]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[97]. Research and Development - The company has a total of 71 authorized patents and is actively developing over 10 products, indicating strong R&D capabilities[35]. - The company is currently in the clinical trial phase for several new blood product lines, aiming to enhance its product offerings and profitability[50]. - The company plans to submit applications for drug registration for several new products, which are expected to enhance its core competitiveness and profit margins[51]. - The company has over 10 products in the rapid development stage, including human prothrombin complex, which is expected to obtain production licensing soon[76]. - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[158]. Governance and Management - The company has established a strong governance structure with experienced board members overseeing its operations[96]. - The company maintained independence from its controlling shareholders in personnel, assets, finance, institutions, and business operations[89]. - The company has a complete and clear ownership of its operational assets, including production equipment and intangible assets[89]. - The company has a robust human resources management system, including independent salary management and accounts[89]. - The company has a management method for subsidiaries to ensure standardized and efficient operations[138]. - The company has a management team with extensive experience in finance and pharmaceuticals, including positions at major financial institutions and pharmaceutical companies[96][97][98]. Financial Management and Audit - The company engaged KPMG Huazhen LLP as its accounting firm for the reporting period[10]. - The audit fee for KPMG Huazhen LLP was CNY 2.2 million for the reporting period[165]. - The total audit fee for the 2022 financial report and internal control audit was RMB 2.2 million, with RMB 1.65 million for the financial report audit and RMB 0.55 million for the internal control audit[169]. - The company maintains an independent financial accounting department and decision-making process[160]. - The company has committed to avoiding or minimizing related party transactions to protect shareholder interests[160]. Shareholder and Dividend Information - The company reported a cash dividend of 0.80 RMB per 10 shares, based on a total of 732,642,692 shares, with no stock bonus issued[2]. - The company’s unallocated profit for the 2022 fiscal year is 1,286,639,844.36 yuan, with 217,808,572.53 yuan available for distribution to shareholders[126]. - The company’s cash dividend distribution accounted for 100% of the total profit distribution amount[126]. - The company has not proposed any cash dividend distribution plan for the previous fiscal year despite having positive distributable profits[125]. Compliance and Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[2]. - The company is committed to adhering to legal regulations and enhancing internal controls to mitigate risks and ensure sustainable development[84]. - The blood products industry faces regulatory risks due to stringent government oversight and evolving policies, which may impact competition and operations[80]. - The company acknowledges the inherent risks in product development, particularly in the innovative biopharmaceutical sector, where high investment and long cycles are common[83]. Social Responsibility and Environmental Initiatives - The company actively participates in social welfare initiatives, including donations for poverty alleviation and healthcare support for patients with hemophilia[152]. - The company has committed to achieving a net profit of no less than RMB 75 million, 120 million, 180 million, and 220 million for the years 2020, 2021, 2022, and 2023 respectively[156]. - The company has received recognition as an advanced unit in legal awareness activities, reflecting its commitment to corporate social responsibility[152]. - The company has implemented environmental protection measures, including wastewater treatment and emissions monitoring, ensuring compliance with regulations[145].

Financial Performance - The company's operating revenue for Q1 2023 was ¥260,860,262.39, a decrease of 47.87% compared to ¥500,420,632.99 in the same period last year[5] - Net profit attributable to shareholders was ¥56,376,087.53, down 46.62% from ¥105,604,403.84 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥36,249,382.73, a decline of 59.73% compared to ¥90,018,691.14 in the previous year[5] - Basic earnings per share decreased to ¥0.0771, down 46.68% from ¥0.1446 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 260,860,262.39, a decrease of 47.9% compared to CNY 500,420,632.99 in the same period last year[18] - The net profit for Q1 2023 was CNY 56,218,316.92, a decrease of 47.1% compared to CNY 106,003,691.20 in the same period last year[19] - Total comprehensive income for Q1 2023 was CNY 56,209,176.61, down 47.1% from CNY 106,009,588.72 in Q1 2022[19] - The total operating profit for Q1 2023 was CNY 63,173,481.12, down 47.4% from CNY 120,103,775.12 in Q1 2022[19] Cash Flow and Assets - The company's cash flow from operating activities increased by 36.56% to ¥106,564,727.56 from ¥78,037,892.32 in the same period last year[5] - Cash flow from operating activities increased to CNY 562,858,056.37, compared to CNY 475,536,500.26 in the previous year, marking a growth of 18.4%[21] - The company's cash and cash equivalents decreased to ¥973,510,301.00 from ¥1,000,797,127.67 at the beginning of the year, a decline of approximately 2.9%[14] - The cash and cash equivalents at the end of Q1 2023 amounted to CNY 973,237,430.92, a decrease from CNY 1,000,270,509.13 at the beginning of the quarter[22] - Total assets at the end of the reporting period were ¥7,925,830,728.13, a slight decrease of 0.71% from ¥7,982,324,465.77 at the end of the previous year[5] - Total current assets decreased to ¥2,985,750,503.88 from ¥3,046,975,789.60, a decline of about 2%[14] - Total liabilities decreased to CNY 1,000,750,529.04 in Q1 2023 from CNY 1,121,197,229.65 in the previous quarter, representing a reduction of 10.8%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period was 23,607[10] - The largest shareholder, Hangzhou Zhemin Investment Partnership, holds 18.35% of shares, totaling 134,464,531 shares[10] - The equity attributable to shareholders increased by 0.92% to ¥6,930,934,944.53 from ¥6,867,524,210.96 at the end of the previous year[5] - The company's equity attributable to shareholders increased to CNY 6,930,934,944.53 from CNY 6,867,524,210.96, reflecting a growth of 0.9%[16] Operational Changes - The company reported a significant increase in other income, which rose by 158.96% to ¥5,208,458.90 due to increased government subsidies[8] - The company experienced a 44.39% improvement in net cash flow from investing activities, which was -¥171,669,347.44 compared to -¥308,715,589.61 in the previous year[8] - The company reported a 175.66% increase in notes receivable, totaling ¥103,663,605.34, primarily due to an increase in commercial bills received during the period[8] - The company has announced a strategic cooperation with Xinjiang Deyuan, indicating plans for future market expansion[12] - The company is in the process of establishing an investment fund in collaboration with professional investment institutions, reflecting a new strategic direction[12] - The company has initiated a share repurchase program, demonstrating confidence in its long-term value[12] Cost and Expenses - Total operating costs for Q1 2023 were CNY 218,309,593.81, down 43.2% from CNY 384,458,625.31 year-over-year[18] - R&D expenses for Q1 2023 were CNY 14,274,385.64, slightly down from CNY 14,574,604.59 in the previous year[18] - The company incurred credit impairment losses of CNY 12,061,663.28 in Q1 2023, compared to a gain of CNY -452,725.42 in the previous year[19] Inventory and Receivables - Trade receivables decreased significantly to ¥460,878,023.27 from ¥835,877,041.68, representing a reduction of about 45%[14] - Inventory increased to ¥788,805,196.76 from ¥623,689,205.55, marking an increase of approximately 26.5%[14] - The company reported a significant increase in trading financial assets, rising to ¥495,663,687.51 from ¥422,435,301.19, an increase of approximately 17.3%[14]

证券代码：000403 证券简称：派林生物 公告编号：2023-027 派斯双林生物制药股份有限公司 关于举行2022年度业绩说明会的公告 （http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次说明会。 二、征集问题事项 为提升交流的针对性和有效性，以便公司在本次说明会上对投资者普遍关注的问 题进行作答，公司现就本次说明会提前向投资者公开征集问题，广泛听取投资者的意 见和建议。投资者可提前登录"互动易"平台，进入"业绩说明会提问预征集"界面 （http://irm.cninfo.com.cn/interview/collect/questionCollect），输入公司股 票代码后进行提问。届时公司将在本次说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与。 特此公告。 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在 巨潮资讯网（http://www.cninfo.com.cn）上披露了《派斯双林生物制药股份有限公 司 2022 ...